Pharmaceutical Executive
Pharmaceutical Executive Podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Episodes
Mentioned books
Oct 16, 2025 • 3min
Pharmaceutical Executive Daily: Rethinking Workforce Development
In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.
Oct 15, 2025 • 3min
Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.
Oct 14, 2025 • 3min
Pharmaceutical Executive Daily: Direct-To-Consumer Trends
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.
Oct 14, 2025 • 11min
Advancing Neuroscience and Rare Disease Innovation
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
Oct 13, 2025 • 3min
Pharmaceutical Executive Daily: Policy Whiplash
In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.
Oct 10, 2025 • 3min
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.
Oct 9, 2025 • 3min
Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.
Oct 8, 2025 • 3min
Pharmaceutical Executive Daily: Amgen Launches New Direct-To-Consumer Platform
In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-consumer platform AmgenNow, and AstraZeneca’s multi-target research partnership with Algen.
Oct 7, 2025 • 3min
Pharmaceutical Executive Daily: FDA Lifts Clinical Hold on NUZ-001
In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’s export ban on Sun Pharma’s Halol facility, and new insights on how small biotechs can better navigate regulatory and market complexities.
Oct 6, 2025 • 3min
Pharmaceutical Executive Daily: Updated Vaccine Recommendations
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, we cover lessons from FDA complete response letters shaping CMC strategy in cell and gene therapy, Takeda’s decision to discontinue its cell therapy research programs, and the CDC’s latest update to COVID-19 vaccination recommendations.
